Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.69 |
| ▸ | GFER | P55789 | 2/20 | 0.69 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.69 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | METAP2 | P50579 | 1/20 | 0.64 |
| ▸ | EP300 | Q09472 | 1/20 | 0.60 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.60 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | CYTH2 | Q99418 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807990 | 0.87 | HSD17B2 (0.69) | GAAGFERAPOBEC3GHSD17B2ALDH1A1 | |
| SCHEMBL7579963 | 0.85 | METAP2 (0.69) | GAAALDH1A1HTTMETAP2MAPT | |
| SCHEMBL10883083 | 0.84 | HSD17B2 (0.70) | GAAGFERAPOBEC3GHSD17B2ALDH1A1 | |
| SCHEMBL9942107 | 0.84 | HSD17B2 (0.61) | GAAHSD17B2ALDH1A1EP300KAT2B | |
| SCHEMBL2616424 | 0.83 | METAP2 (0.63) | GAAALDH1A1HTTMETAP2MAPT | |
| SCHEMBL9345894 | 0.82 | GAA (1.00) | GAAGFERAPOBEC3GHSD17B2ALDH1A1 | |
| SCHEMBL12767988 | 0.81 | HSD17B2 (0.65) | GAAGFERHSD17B2ALDH1A1HTT | |
| SCHEMBL6802646 | 0.81 | ERBB2 (0.77) | GAAGFERAPOBEC3GHSD17B2ALDH1A1 | |
| SCHEMBL16438044 | 0.81 | METAP2 (0.60) | GAAALDH1A1HTTMETAP2MAPT | |
| SCHEMBL12767911 | 0.80 | GAA (0.64) | GAAGFERAPOBEC3GHSD17B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962244-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-22 | — | — | US | disclosed |
| US-8377639-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | GAA 3022/4885GFER 3541/4885APOBEC3G 2006/4885 |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | GAA 3022/4885GFER 3541/4885APOBEC3G 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.